乳腺外科
おしらせ
《 乳腺外科外来の初診について（診療体制変更のご案内）》
2026年4月より、乳腺外科の初診外来は
月曜日・金曜日の9:00～10:30の予約枠 に変更いたします。
＊火曜日・木曜日は再診のみとなり、初診の方の診察は行っておりません。
水曜日は手術日のため外来診療は行っておりません。
受診をご希望の方は、かかりつけ医療機関を通じて事前にご予約をお願いいたします。
ご予約の方は、診療の準備（データ取り込みや診察前検査など）がございますので、
予約時間の30分前までにご来院くださいますようご協力をお願いいたします。
また乳がん検診や人間ドック等の結果で「要精密検査」となった方は、
検診結果と紹介状（精密検査の依頼書）をお持ちのうえ、
月曜日・金曜日の8:45～11:30の診療受付時間内にご来院ください。
なお、その場合も月曜日・金曜日以外の曜日は対応しておりませんのでご了承ください。
2026年4月より、乳腺外科の初診外来は
月曜日・金曜日の9:00～10:30の予約枠 に変更いたします。
＊火曜日・木曜日は再診のみとなり、初診の方の診察は行っておりません。
水曜日は手術日のため外来診療は行っておりません。
受診をご希望の方は、かかりつけ医療機関を通じて事前にご予約をお願いいたします。
ご予約の方は、診療の準備（データ取り込みや診察前検査など）がございますので、
予約時間の30分前までにご来院くださいますようご協力をお願いいたします。
また乳がん検診や人間ドック等の結果で「要精密検査」となった方は、
検診結果と紹介状（精密検査の依頼書）をお持ちのうえ、
月曜日・金曜日の8:45～11:30の診療受付時間内にご来院ください。
なお、その場合も月曜日・金曜日以外の曜日は対応しておりませんのでご了承ください。
診療科のご案内
乳腺外科領域では、乳腺疾患およびそれにまつわる脇の下（腋窩）のリンパ節などに対する診療を行っています。
乳腺疾患としては自覚症状があるときや、検診で異常を指摘された際の精密検査を行い、乳がんの診断から初発時治療（手術、薬物療法）から再発治療まで対応しております。外来・病棟看護師はもちろんのこと、放射線診断科・治療科、病理診断科、化学療法室、薬剤科をはじめとした院内の各部署とチーム医療で診療にあたっています。
乳腺疾患としては自覚症状があるときや、検診で異常を指摘された際の精密検査を行い、乳がんの診断から初発時治療（手術、薬物療法）から再発治療まで対応しております。外来・病棟看護師はもちろんのこと、放射線診断科・治療科、病理診断科、化学療法室、薬剤科をはじめとした院内の各部署とチーム医療で診療にあたっています。
乳腺疾患の診断・治療
常勤の乳腺専門医が乳腺疾患の診断、乳がんの診断から治療まで当科にて一貫して行います。
診断にはトモシンセシス機能を備えたマンモグラフィ装置、エコー検査、CT、3.0テスラのMRIを用いており、さらに針生検・乳腺腫瘍画像ガイド下吸引術による組織診や穿刺吸引細胞診などを行っておりますが、その中においても放射線科、病理診断科ともディスカッションを行い、多角的に検討をしています。
治療については、乳癌診療ガイドラインに沿った標準治療を基本とし、その中で患者さん一人ひとりに合わせた治療選択をするようにしています。
乳がんの治療における薬物療法も近年様々な種類の薬剤が用いられるようになり、ホルモン療法、抗がん剤治療以外にも、分子標的治療薬、免疫チェックポイント阻害薬などは手術とならんで重要な役割を果たしており、安全に、安心してこれらの治療を進めていけるよう、化学療法認定看護師を中心としてチーム医療で患者さんのサポートに努めています。
当科ではこれらの初期治療だけでなく、再発治療まで行っていく中で、それに伴う不安や症状などに対しても、『早期からの緩和ケア』としてどのタイミングでも多部門によるチームで連携をして、患者さんの治療、生活を全力で支えていくよう心がけています。
診断にはトモシンセシス機能を備えたマンモグラフィ装置、エコー検査、CT、3.0テスラのMRIを用いており、さらに針生検・乳腺腫瘍画像ガイド下吸引術による組織診や穿刺吸引細胞診などを行っておりますが、その中においても放射線科、病理診断科ともディスカッションを行い、多角的に検討をしています。
治療については、乳癌診療ガイドラインに沿った標準治療を基本とし、その中で患者さん一人ひとりに合わせた治療選択をするようにしています。
乳がんの治療における薬物療法も近年様々な種類の薬剤が用いられるようになり、ホルモン療法、抗がん剤治療以外にも、分子標的治療薬、免疫チェックポイント阻害薬などは手術とならんで重要な役割を果たしており、安全に、安心してこれらの治療を進めていけるよう、化学療法認定看護師を中心としてチーム医療で患者さんのサポートに努めています。
当科ではこれらの初期治療だけでなく、再発治療まで行っていく中で、それに伴う不安や症状などに対しても、『早期からの緩和ケア』としてどのタイミングでも多部門によるチームで連携をして、患者さんの治療、生活を全力で支えていくよう心がけています。
主な疾患・治療法
乳腺疾患一般（乳癌、良性腫瘍、良性疾患）の診断、治療（手術、薬物療法ほか）
診療実績・研究業績
論文掲載
（欧文誌 2020年から）
1. ＊Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
Factors Associated With Prolonged Overall Survival in Patients With Postmenopausal Estrogen Receptor-Positive Advanced Breast Cancer Using Real-World Data: A Follow-Up Analysis of the JBCRG-C06 Safari Study.
Breast Cancer. 2020, 27(3):389-98, 31811519
2. Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S.
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Breast Cancer. 2021, 28(1):145-60, 32715420
3. Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M.
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Invest New Drugs. 2021, 39(1):217-25, 32833136
4. Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int. J. Clin. Oncol. 2021, 26(7):1229-1236, 33891194
5. ＊Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol. 2022, 52(6):545-553, 35296894
6. Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol. 2022, 27(11):1793, 36166110
7. ＊Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol. 2023, 53(3):203-11, 36484305
8. Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S.
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Cancer Med. 2023, 12(17):17718-30, 37525895
9. Kobayashi K, Hata A, Imoto W, Kakuno S, Shibata W, Yamada K, Kawaguchi H, Sakurai N, Nakaie K, Nakatsuka Y, Ito T, Uenoyama K, Takahashi T, Ueda S, Katayama T, Onoue M, Kakeya H.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Breast Cancer Res Treat. 2023, 201(3):409-415, 37480384
10. Niwa Y, Terada M, Wanifuchi-Endo Y, Fujita T, Asano T, Kawaguchi H, Nozawa K, Matsumoto N, Isogai A, Kawahara H, Mizumoto M, Toyama T.
Predictive factors and prognostic significance of HER2-low early breast cancer with long-term follow-up.
Surg Oncol. 2026 Feb;64:102360. doi: 10.1016/j.suronc.2026.102360. Epub 2026 Feb 4.
（欧文誌 2020年から）
1. ＊Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
Factors Associated With Prolonged Overall Survival in Patients With Postmenopausal Estrogen Receptor-Positive Advanced Breast Cancer Using Real-World Data: A Follow-Up Analysis of the JBCRG-C06 Safari Study.
Breast Cancer. 2020, 27(3):389-98, 31811519
2. Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S.
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Breast Cancer. 2021, 28(1):145-60, 32715420
3. Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M.
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Invest New Drugs. 2021, 39(1):217-25, 32833136
4. Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int. J. Clin. Oncol. 2021, 26(7):1229-1236, 33891194
5. ＊Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol. 2022, 52(6):545-553, 35296894
6. Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol. 2022, 27(11):1793, 36166110
7. ＊Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol. 2023, 53(3):203-11, 36484305
8. Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S.
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Cancer Med. 2023, 12(17):17718-30, 37525895
9. Kobayashi K, Hata A, Imoto W, Kakuno S, Shibata W, Yamada K, Kawaguchi H, Sakurai N, Nakaie K, Nakatsuka Y, Ito T, Uenoyama K, Takahashi T, Ueda S, Katayama T, Onoue M, Kakeya H.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Breast Cancer Res Treat. 2023, 201(3):409-415, 37480384
10. Niwa Y, Terada M, Wanifuchi-Endo Y, Fujita T, Asano T, Kawaguchi H, Nozawa K, Matsumoto N, Isogai A, Kawahara H, Mizumoto M, Toyama T.
Predictive factors and prognostic significance of HER2-low early breast cancer with long-term follow-up.
Surg Oncol. 2026 Feb;64:102360. doi: 10.1016/j.suronc.2026.102360. Epub 2026 Feb 4.
学会発表
国際学会 （2017年から）
1. Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer. (JBCRG-M03).
Narui K, Yamashita T, Kitada M, Kawaguchi H, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Masuda N, Morita S, Ohno S, Toi M.
American Society of Clinical Oncology (ASCO). 2017, Poster
2. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer: A subgroup analysis of the JBCRG-C06 Safari study.
＊Kawaguchi H, Aogi K, Masuda N, Nakayama T, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
European Society For Medical Oncology (ESMO). 2017, Poster
3. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advance Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer (JBCRG-M03).
＊Kawaguchi H, Yamashita T, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M.
San Antonio Breast Cancer Symposium (SABCS). 2017, Poster
4. Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: a phase II randomized study (JBCRG-19).
Aogi K, Kawaguchi H, Masuda N, Nakayama T, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
European Society for Medical Oncology (ESMO). 2018, Poster
5. Factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study.
Aogi K, Kawaguchi H, Masuda N, Nakayama T, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
San Antonio Breast Cancer Symposium (SABCS). 2019, Poster
6. Outcomes of fulvestrant therapy among Japanese women with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of the Japan Breast Cancer Research Group (JBCRG)-C06 Safari study.
Hagi M, Kawaguchi H, Masuda N, Saji S, Yamamoto Y, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Morita S, Toi M, Ohno S.
San Antonio Breast Cancer Symposium (SABCS). 2019, Poster
7. Influence of the adjuvant hormonal therapy on hormone sensitivity and survival outcomes in ER+ and HER2−advanced breast cancer: A subgroup analysis of the JBCRG-C06 Safari study.
Nakayama T, Kawaguchi H, Masuda N, Saji S, Yamamoto Y, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Morita S, Toi M, Ohno S.
San Antonio Breast Cancer Symposium (SABCS). 2019, Poster
8. Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study.
Utsunomiya K, Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S.
San Antonio Breast Cancer Symposium (SABCS). 2022, Poster
9. Prospective study on eribulin efficacy in advanced and metastatic breast cancer: changes in TGF-β compared to other standard chemotherapy agents. (KBCSG-TR 2018, POTENTIAL).
Nakayama T, Yoshinami T, Fujisawa F, Nishio M, Yamanaka T, Yamashita T, Oshiro C, Izui A, Tomioka N, Maeda H, Shimoda M, Shimazu K, Tsuneizumi I, Matsunuma R, Bando H, Ueda A, Yasojima H, Okada K, Inoue K, Kai Y, Yoshidome K, Kawaguchi H, Nagahashi M, Oshima K, Kashiwagi S, Iwasa T, Taruno K, Tsuyuki S, Tsukamoto F, Morimoto T, Kittaka N, Higuchi T, Naito Y, Saita R, Nishikawa H, Sugiyama D, Miyoshi Y, Uchida Y, Yamada T, Masuda N.
San Antonio Breast Cancer Symposium (SABCS). 2023, Poster
国際学会 （2017年から）
1. Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer. (JBCRG-M03).
Narui K, Yamashita T, Kitada M, Kawaguchi H, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Masuda N, Morita S, Ohno S, Toi M.
American Society of Clinical Oncology (ASCO). 2017, Poster
2. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer: A subgroup analysis of the JBCRG-C06 Safari study.
＊Kawaguchi H, Aogi K, Masuda N, Nakayama T, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
European Society For Medical Oncology (ESMO). 2017, Poster
3. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advance Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer (JBCRG-M03).
＊Kawaguchi H, Yamashita T, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M.
San Antonio Breast Cancer Symposium (SABCS). 2017, Poster
4. Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: a phase II randomized study (JBCRG-19).
Aogi K, Kawaguchi H, Masuda N, Nakayama T, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
European Society for Medical Oncology (ESMO). 2018, Poster
5. Factors associated with prolonged post-recurrence survival in patients with postmenopausal estrogen receptor-positive breast cancer taking fulvestrant: A follow-up data of the JBCRG-C06 Safari study.
Aogi K, Kawaguchi H, Masuda N, Nakayama T, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
San Antonio Breast Cancer Symposium (SABCS). 2019, Poster
6. Outcomes of fulvestrant therapy among Japanese women with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of the Japan Breast Cancer Research Group (JBCRG)-C06 Safari study.
Hagi M, Kawaguchi H, Masuda N, Saji S, Yamamoto Y, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Morita S, Toi M, Ohno S.
San Antonio Breast Cancer Symposium (SABCS). 2019, Poster
7. Influence of the adjuvant hormonal therapy on hormone sensitivity and survival outcomes in ER+ and HER2−advanced breast cancer: A subgroup analysis of the JBCRG-C06 Safari study.
Nakayama T, Kawaguchi H, Masuda N, Saji S, Yamamoto Y, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Morita S, Toi M, Ohno S.
San Antonio Breast Cancer Symposium (SABCS). 2019, Poster
8. Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study.
Utsunomiya K, Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S.
San Antonio Breast Cancer Symposium (SABCS). 2022, Poster
9. Prospective study on eribulin efficacy in advanced and metastatic breast cancer: changes in TGF-β compared to other standard chemotherapy agents. (KBCSG-TR 2018, POTENTIAL).
Nakayama T, Yoshinami T, Fujisawa F, Nishio M, Yamanaka T, Yamashita T, Oshiro C, Izui A, Tomioka N, Maeda H, Shimoda M, Shimazu K, Tsuneizumi I, Matsunuma R, Bando H, Ueda A, Yasojima H, Okada K, Inoue K, Kai Y, Yoshidome K, Kawaguchi H, Nagahashi M, Oshima K, Kashiwagi S, Iwasa T, Taruno K, Tsuyuki S, Tsukamoto F, Morimoto T, Kittaka N, Higuchi T, Naito Y, Saita R, Nishikawa H, Sugiyama D, Miyoshi Y, Uchida Y, Yamada T, Masuda N.
San Antonio Breast Cancer Symposium (SABCS). 2023, Poster
こちらの「診療実績・研究実績」は、当院外科（消化器外科、呼吸器外科、乳腺外科、その他の一般外科）のものです。
